Effects of salidroside on glioma formation and growth inhibition together with improvement of tumor microenvironment.

OBJECTIVE To test the effects of salidroside on formation and growth of glioma together with tumor microenvironment. METHODS Salidroside extracted from Rhodiola rosea was purified and treated on human glioma cells U251 at the concentration of 20 µg/mL. 3-(4,5-dimethylthiazol-2-yl)-2,5-dephenyltetrazolium bromide (MTT) assay for cytotoxicity and flow cytometry (FCM) for cell cycle analysis were performed. Then for in vivo study, xenotransplantation tumor model in nude mice was generated and treated with salidroside at the concentration of 50 mg/kg(.)d for totally 20 d. Body weight and tumor size were detected every 2 d after the treatment. The levels of 8-isoprostane, superoxide dismutase (SOD) and malondialdehyde (MDA), special markers for oxidative stress, were detected while immunofluoresence staining was performed for astrocyte detection. RESULTS For in vitro study, salidroside could decrease the viability of human glioma cells U251 and the growth of U251 cells at G0/G1 checkpoint during the cell cycle. For in vivo study, salidroside could also inhibit the growth of human glioma tissue in nude mice. The body weight of these nude mice treated with salidroside did not decrease as quickly as control group. In the tumor xenotransplantation nude mice model, mice were found of inhibition of oxidative stress by detection of biomarkers. Furthermore, overgrowth of astrocytes due to the stimulation of oxidative stress in the cortex of brain was inhibited after the treatment of salidroside. CONCLUSIONS Salidroside could inhibit the formation and growth of glioma both in vivo and in vitro and improve the tumor microenvironment via inhibition of oxidative stress and astrocytes.

[1]  Stephen Clarke,et al.  Pharmacokinetics and Pharmacodynamics of Intraperitoneal Cancer Chemotherapeutics , 2012, Clinical Pharmacokinetics.

[2]  T. Hung,et al.  Salidroside Improves Behavioral and Histological Outcomes and Reduces Apoptosis via PI3K/Akt Signaling after Experimental Traumatic Brain Injury , 2012, PloS one.

[3]  A. Mattox,et al.  Marked response of gliomatosis cerebri to temozolomide and whole brain radiotherapy , 2012, Clinical Neurology and Neurosurgery.

[4]  B. Halliwell Free radicals and antioxidants: updating a personal view. , 2012, Nutrition reviews.

[5]  P. Ray,et al.  Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. , 2012, Cellular signalling.

[6]  Chi V Dang,et al.  Links between metabolism and cancer. , 2012, Genes & development.

[7]  David H Rowitch,et al.  Astrocytes and disease: a neurodevelopmental perspective. , 2012, Genes & development.

[8]  C. Giaume,et al.  Glial hemichannels and their involvement in aging and neurodegenerative diseases , 2012, Reviews in the neurosciences.

[9]  C. Patil,et al.  Management of multifocal and multicentric gliomas. , 2012, Neurosurgery clinics of North America.

[10]  Chae-Yong Kim,et al.  Current surgical management of insular gliomas. , 2012, Neurosurgery clinics of North America.

[11]  Dario J. Englot,et al.  Characteristics and treatment of seizures in patients with high-grade glioma: a review. , 2012, Neurosurgery clinics of North America.

[12]  Á. Almeida,et al.  Antioxidant and bioenergetic coupling between neurons and astrocytes. , 2012, The Biochemical journal.

[13]  L. Bujanda,et al.  Mouse models of pancreatic cancer. , 2012, World journal of gastroenterology.

[14]  N. Curtin,et al.  Targeting the S and G2 checkpoint to treat cancer. , 2012, Drug discovery today.

[15]  K. Hoang-Xuan,et al.  Primary brain tumours in adults , 2003, The Lancet.

[16]  Christopher M. Jackson,et al.  Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment , 2011, Clinical & developmental immunology.

[17]  K. Debatin,et al.  Diversity of human leukemia xenograft mouse models: implications for disease biology. , 2011, Cancer research.

[18]  H. Dvorak,et al.  Tumor microenvironment and progression , 2011, Journal of surgical oncology.

[19]  E. Ernst,et al.  The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. , 2011, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[20]  M. Chamberlain Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas , 2010, Expert review of neurotherapeutics.

[21]  J. Sarris,et al.  Rosenroot (Rhodiola rosea): traditional use, chemical composition, pharmacology and clinical efficacy. , 2010, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[22]  J. Morrison,et al.  Friend or foe? Resolving the impact of glial responses in glaucoma. , 2009, Journal of glaucoma.